Prognostic value of Caveolin‐1 in patients treated with radical prostatectomy: a multicentric validation study

No abstract is available for this paper.

• Publication year

  2016

• Venue

  BJU International

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.13224PMID 26189876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2015

  2015cited by this paper
• Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy

  2015cited by this paper
• EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

  2014cited by this paper
• Caveola-forming proteins caveolin-1 and PTRF in prostate cancer

  2013cited by this paper
• PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.

  2012cited by this paper
• Anti-caveolin-1 Antibodies As Anti-Prostate Cancer Therapeutics

  2012cited by this paper
• A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.

  2011cited by this paper
• The role of caveolin-1 in prostate cancer: clinical implications

  2010cited by this paper
• Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

  2010cited by this paper
• Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression

  2009cited by this paper
• Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer

  2008cited by this paper
• Caveolin-1 in tumor progression: the good, the bad and the ugly

  2008cited by this paper
• Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.

  2008cited by this paper
• Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence

  2007cited by this paper
• Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

  2006cited by this paper
• Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer

  2006cited by this paper
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

  2005cited by this paper
• Caveolin, cholesterol, and lipid bodies.

  2005cited by this paper
• Combined c‐Myc and caveolin‐1 expression in human prostate carcinoma predicts prostate carcinoma progression

  2005cited by this paper
• Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.

  2004cited by this paper
• Caveolin‐1 expression is a predictor of recurrence‐free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients

  2003cited by this paper
• Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.

  2003cited by this paper
• Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

  2003cited by this paper
• Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

  2002cited by this paper
• Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer.

  2001cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.

  1999cited by this paper
• Elevated expression of caveolin is associated with prostate and breast cancer.

  1998cited by this paper
• Fresh tissue harvest for research from prostatectomy specimens

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• Exosomal Prostate-Specific Membrane Antigen (PSMA) and Caveolin-1 as Potential Biomarkers of Prostate Cancer—Evidence from Serbian Population

  2024cites this paper
• Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

  2023cites this paper
• Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs)

  2021cites this paper
• Caveola-forming proteins and prostate cancer

  2020influential citation
• Effect of Palmitic Acid on Exosome-Mediated Secretion and Invasive Motility in Prostate Cancer Cells

  2020cites this paper
• The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems

  2020cites this paper
• Caveolin-1 in renal disease

  2018cites this paper
• Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes.

  2018cites this paper
• Caveolin-1 in renal disease

  2018cites this paper
• Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores

  2018cites this paper
• Prognostic significance of epithelial/stromal caveolin-1 expression in prostatic hyperplasia, high grade prostatic intraepithelial hyperplasia and prostatic carcinoma and its correlation with microvessel density.

  2017cites this paper
• Myosin isoform expressed in metastatic prostate cancer stimulates cell invasion

  2017cites this paper
• Caveolin-1 Expression in Upper Tract Urothelial Carcinoma.

  2017cites this paper
• Missing-in-metastasis B (MIM-B) combined with caveolin-1 promotes metastasis of hepatocellular carcinoma

  2017cites this paper
• Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.

  2017cites this paper